Showing results (671-680 of 3,079) with videos related to
Sort By:
Pageof 308
Drug Safety|October 17, 2025
Anticholinergic Drug Use in Elderly Patients: Compliance with STOPP-START and BEERS Criteria in Spain-A Descriptive StudyJavier Santandreu, Francisco Félix Caballero, Elena González-BurgosDrug Safety|October 1, 2025
Statistical Methods for Multi-jurisdictional Australian Vaccine Safety Investigations of Rare Adverse EventsHannah J Morgan, Lauren Bloomfield, Hazel J Clothier, et al.Drug Safety|June 20, 2020
Association Between Intravitreal Aflibercept and Serious Non-ocular Haemorrhage Compared with Intravitreal Ranibizumab: A Multicentre Observational Cohort StudyJanet Sultana, Francesco Giorgianni, Giulia Scondotto, et al.Drug Safety|June 20, 2020
Comparative Outcomes Between Direct Oral Anticoagulants, Warfarin, and Antiplatelet Monotherapy Among Chinese Patients with Atrial Fibrillation: A Population-Based Cohort StudyXue Li, Swathi Pathadka, Kenneth K C Man, et al.Drug Safety|July 31, 2022
Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated TrialsMorten Schmidt, Henrik Toft Sørensen, Lars PedersenDrug Safety|October 21, 2019
Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort StudySamy Babai, Anne-Laure Voisin, Célia Bertin, et al.Drug Safety|October 27, 2019
Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes MellitusKohei Kaku, Koichi Kisanuki, Mari Shibata, et al.Drug Safety|April 25, 2020
Oxycodone, Hydromorphone, and the Risk of Suicide: A Retrospective Population-Based Case-Control StudyGraham Mazereeuw, Tara Gomes, Erin M Macdonald, et al.Drug Safety|April 20, 2020
DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes MellitusAntoine Pariente, Vanessa Labat, Yohann Mansiaux, et al.Drug Safety|September 16, 2025
Characterizing the FDA Adverse Event Reporting System (FAERS) as a Network to Improve Pattern DiscoveryRaechel Davis, Oanh Dang, Suranjan De, et al.Pageof 308